Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$4.50 USD
+0.56 (14.21%)
Updated Sep 19, 2024 04:00 PM ET
Pre-Market: $4.46 -0.04 (-0.89%) 8:18 AM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.50 USD
+0.56 (14.21%)
Updated Sep 19, 2024 04:00 PM ET
Pre-Market: $4.46 -0.04 (-0.89%) 8:18 AM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Zacks News
Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Monopar Therapeutics (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy
by Zacks Equity Research
Monopar Therapeutics (MNPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Monopar Therapeutics Inc. (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
by Zacks Equity Research
Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Monopar Therapeutics Inc. (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Monopar Therapeutics Inc. (MNPR) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Monopar Therapeutics (MNPR) Catches Eye: Stock Jumps 11.2%
by Zacks Equity Research
Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
Blueprint Medicines Gets CRL for Ayvakit in Fourth-Line Gist
by Zacks Equity Research
The FDA issues a CRL to Blueprint Medicines' (BPMC) NDA for Ayvakit to treat adults with unresectable/metastatic fourth-line GST.